City Safety by Volvo Cars – outstanding crash prevention that is standard in the all-new XC90 - Volvo Car USA Newsroom
![5 Projects from Underwriters Laboratories Featured for WHO / Public Health Association of Australia Conference | Underwriters Laboratories 5 Projects from Underwriters Laboratories Featured for WHO / Public Health Association of Australia Conference | Underwriters Laboratories](https://ul.org/sites/default/files/styles/article/public/2021-04/injury-prevention-journal-cover-collage.jpg?itok=j-uEeSum)
5 Projects from Underwriters Laboratories Featured for WHO / Public Health Association of Australia Conference | Underwriters Laboratories
DSP Design Associates - Cyber exploitation is a serious threat that comes along with the rapidly advancing technology for smart systems. Fred Gordy, Director of Cybersecurity, Intelligent Buildings — our partner firm,
![Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India - eClinicalMedicine Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e7a2e829-a8a6-4767-9da1-8e764d5c37ae/gr1.jpg)
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India - eClinicalMedicine
![Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial - The Lancet Infectious Diseases Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/75b95593-73fe-4e86-8fcc-e89d28bf75ce/gr1.gif)